Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 36

Sort by

Sort Order Select

Journal Articles

Efficacy and Safety of Sevuparin, a Novel Non-Anti-Coagulant Heparinoid, in Patients with Acute Painful Vaso-Occlusive Crisis; A Global, Multicenter Double-Blind, Randomized, Placebo-Controlled Phase 2 Trial (TVOC01)

Bart J. Biemond, MD PhD, Anil Tombak, MD, Yurdanur Kilinc, MD, Murtadha Al-Khabori, MD, Miguel R. Abboud, MD, Mohammed Nafea, MD, Adlette Inati, MD, Yasser Ahmed Mohamed Soliman Wali, MD, Jens Kristensen, MD PhD, Ellen Donnelly, PhD, John Ohd, MD PhD

Blood (2019) 134 (Supplement_1): 614.

https://doi.org/10.1182/blood-2019-124653

Published: 2019

Journal Articles

Decreased Activity and Stability of Pyruvate Kinase in Hereditary Hemolytic Anemia: A Potential Target for Therapy By AG-348 (Mitapivat), an Allosteric Activator of Red Blood Cell Pyruvate Kinase

Minke A.E. Rab, MD, Brigitte A. van Oirschot, Stephanie van Straaten, MD PhD, Bart J. Biemond, MD PhD, Jennifer Bos, Penelope A. Kosinski, MS, Charles Kung, PhD, Eduard J. van Beers, MD PhD, Richard van Wijk, PhD

Blood (2019) 134 (Supplement_1): 3506.

https://doi.org/10.1182/blood-2019-129996

Published: 2019

Journal Articles

Genetic Association Studies of Red Blood Cell Transfusion Related Alloimmunization: A Systematic Review and Meta-Analysis

Jorn Gerritsma, MD, Ilja Oomen, BSc, Sanne Meinderts, PhD, C. Ellen van der Schoot, MD PhD, Bart J. Biemond, MD PhD, Johanna G van der Bom, MD PhD, Karin Fijnvandraat, MD PhD

Blood (2019) 134 (Supplement_1): 2459.

https://doi.org/10.1182/blood-2019-128199

Published: 2019

Journal Articles

Complications of Extra Fluid Therapy (Hyperhydration) in Sickle Cell Patients during Vaso-Occlusive Painful Crisis

Aafke E. Gaartman, MD, Ajab K. Sayedi, BSc, Charlotte F.J. Van Tuijn, MPH, PhD, Harriet Heijboer, MD PhD, Tanja Netelenbos, MD PhD, Bart J. Biemond, MD PhD, Erfan Nur, MD PhD

Blood (2019) 134 (Supplement_1): 1024.

https://doi.org/10.1182/blood-2019-130248

Published: 2019

Journal Articles

Proton Pump Inhibition for Secondary Hemochromatosis in Hereditary Anemia, a Phase III Placebo Controlled Randomized Cross-over Trial in Progress

Annelies J. Van Vuren, MD, Bart J. Biemond, MD PhD, Jean-Louis Kerkhoffs, MD PhD, Saskia E.M. Schols, MD PhD, A. W. Rijneveld, MD PhD, Erfan Nur, MD PhD, Richard van Wijk, PhD, Tim Leiner, MD PhD, Joannes J.M. Marx, Emeritus Professor, Eduard J. van Beers, MD PhD

Blood (2019) 134 (Supplement_1): 960.

https://doi.org/10.1182/blood-2019-124059

Published: 2019

Journal Articles

Adding Azathioprine and Hydroxyurea Preconditioning to Alemtuzumab/TBI May Improve Donor Chimerism in Matched Sibling Donor Allogeneic Stem Cell Transplantation in Adult Sickle Cell Patients

Erfan Nur, MD PhD, Sacha S Zeerleder, MD PhD, Aafke E. Gaartman, MD, Caroline E Rutten, MD PhD, Charlotte F.J. Van Tuijn, MPH, PhD, Liesbeth E.M. Suijk, Mette D Hazenberg, MD PhD, Bart J. Biemond, MD PhD

Blood (2019) 134 (Supplement_1): 997.

https://doi.org/10.1182/blood-2019-129403

Published: 2019

Journal Articles

Association of Endothelial Biomarkers with Cerebral MRI Perfusion Analysis in Patients with Sickle Cell Disease

Liza Afzali-Hashemi, Lena Vaclavu, PhD, Erfan Nur, MD PhD, Aart J Nederveen, PhD, Bart J. Biemond, MD PhD

Blood (2019) 134 (Supplement_1): 1000.

https://doi.org/10.1182/blood-2019-124688

Published: 2019

Journal Articles

High Incidence and Recurrence Rate of Venous Thromboembolic Events in Patients with Sickle Cell Disease

Bart J. Biemond, MD PhD, Ewout R. Egner, MD, Erfan Nur, MD PhD, Charlotte F.J. Van Tuijn, MPH, PhD

Blood (2018) 132 (Supplement 1): 2381.

https://doi.org/10.1182/blood-2018-99-119343

Published: 2018

Journal Articles

Incentive Spirometry to Prevent Acute Chest Syndrome in Adults with Sickle Cell Disease

Bart J. Biemond, MD PhD, Charlotte F.J. Van Tuijn, MPH, PhD, Aafke E. Gaartman, MD, Erfan Nur, MD PhD, A. W. Rijneveld, MD PhD

Blood (2018) 132 (Supplement 1): 3660.

https://doi.org/10.1182/blood-2018-99-117450

Published: 2018

Journal Articles

The High Output State of Sickle Cell Patients: Associations with Anemia-Related Organ Damage

Bart J. Biemond, MD PhD, Tim R. de Back, MD, Charlotte F.J. Van Tuijn, MPH, PhD, Erfan Nur, MD PhD, Berto J. Bouma, MD PhD

Blood (2018) 132 (Supplement 1): 3661.

https://doi.org/10.1182/blood-2018-99-117501

Published: 2018

Journal Articles

Reduced Cerebral Metabolic Rate of Oxygen in Adults with Sickle Cell Disease

Lena Vaclavu, Esben Thade Petersen, PhD, Ed T VanBavel, PhD, Charles BL Majoie, MD PhD, Aart J Nederveen, PhD, Bart J. Biemond, MD PhD

Blood (2018) 132 (Supplement 1): 11.

https://doi.org/10.1182/blood-2018-99-116194

Published: 2018

Journal Articles

Reduced Cerebrovascular Reserve Capacity in Adults with Sickle Cell Disease

Lena Vaclavu, MSc, Lena Vaclavu, Henri JMM Mutsaerts, PhD, Esben Thade Petersen, PhD, Ed T VanBavel, PhD, John C Wood, MD PhD, Charles BL Majoie, MD PhD, Aart J Nederveen, PhD, Bart J. Biemond, MD PhD

Blood (2017) 130 (Supplement 1): 972.

https://doi.org/10.1182/blood.V130.Suppl_1.972.972

Published: 2017

Journal Articles

Predictive Value of Gradual Change in Renal Function on Vasculopathy Related Complications and Mortality in Patients with Sickle Cell Disease

Bart J. Biemond, MD PhD, Weel Elsita, Charlotte F.J. Van Tuijn, MPH, Erfan Nur, MD PhD, Liffert Vogt, MDPhD

Blood (2017) 130 (Supplement 1): 986.

https://doi.org/10.1182/blood.V130.Suppl_1.986.986

Published: 2017

Journal Articles

Prospective Molecular MRD Detection By NGS: A Powerful Independent Predictor for Relapse and Survival in Adults with Newly Diagnosed AML

Blood (2017) 130 (Supplement 1): LBA-5.

https://doi.org/10.1182/blood.V130.Suppl_1.LBA-5.LBA-5

Published: 2017

Journal Articles

Clofarabin Added to Standard Treatment in Adult Patients with Newly Diagnosed ALL: First Results of the Randomized Phase III HOVON-100 Study

Blood (2017) 130 (Supplement 1): 2606.

https://doi.org/10.1182/blood.V130.Suppl_1.2606.2606

Published: 2017

Journal Articles

Randomized Maintenance Therapy with Azacitidine (Vidaza) in Older Patients (≥ 60 years of age) with Acute Myeloid Leukemia (AML) and Refractory Anemia with Excess of Blasts (RAEB, RAEB-t). Results of the HOVON97 Phase III Randomized Multicentre Study (EudraCT 2008-001290-15)

Geert Huls, MD PhD, Dana Chitu, Violaine Havelange, Mojca Jongen-Lavrencic, MD PhD, Arjen van de Loosdrecht, Bart J. Biemond, MD PhD, Harm Sinnege, MDPhD, Beata Hodossy, Carlos Graux, Marinus van Marwijk Kooij, MD PhD, Okke de Weerdt, MD, Dimitri Breems, MD PhD, Saskia Klein, MD, Jurgen Kuball, MD, Gert J. Ossenkoppele, MD PhD, Bob Lowenberg, MD PhD, Edo Vellenga, MD

Blood (2017) 130 (Supplement 1): 463.

https://doi.org/10.1182/blood.V130.Suppl_1.463.463

Published: 2017

Journal Articles

Effects of Oral N -Acetylcysteine on Oxidative Stress in Patients with Sickle Cell Disease

Blood (2017) 130 (Supplement 1): 2244.

https://doi.org/10.1182/blood.V130.Suppl_1.2244.2244

Published: 2017

Journal Articles

Free Iron in Sera of Patients with Sickle Cell Disease Contributes to the Release of Neutrophil Extracellular Traps

Kristof Van Avondt, PhD, Marein Schimmel, Ingrid Bulder, Robin van Bruggen, PhD, Bart J. Biemond, MD PhD, Brenda M. Luken, PhD, Sacha S. Zeerleder, MD PhD

Blood (2016) 128 (22): 161.

https://doi.org/10.1182/blood.V128.22.161.161

Published: 2016

Journal Articles

N-Acetylcysteine in Patients with Sickle Cell Disease: A Randomized Controlled Trial

Blood (2016) 128 (22): 123.

https://doi.org/10.1182/blood.V128.22.123.123

Published: 2016

Journal Articles

Post-Remission Treatment with Allogeneic Stem Cell Transplantation Improves Outcome in Patients Aged 60 Years and Older with Acute Myeloid Leukemia in First Remission

Jurjen Versluis, MD, Carin L.E. Hazenberg, MD, Wim van Putten, MSc, Jakob R Passweg, MD, Johan Maertens, MD PhD, Bart J Biemond, MD PhD, Harry C Schouten, MDPhD, Thomas Pabst, MD, Bob Lowenberg, MDPhD, Gert J Ossenkoppele, MDPhD, Edo Vellenga, MDPhD, Jan J Cornelissen, MD PhD

Blood (2014) 124 (21): 321.

https://doi.org/10.1182/blood.V124.21.321.321

Published: 2014

NARROW

Efficacy and Safety of Sevuparin, a Novel Non-Anti-Coagulant Heparinoid, in Patients with Acute Painful Vaso-Occlusive Crisis; A Global, Multicenter Double-Blind, Randomized, Placebo-Controlled Phase 2 Trial (TVOC01)

Decreased Activity and Stability of Pyruvate Kinase in Hereditary Hemolytic Anemia: A Potential Target for Therapy By AG-348 (Mitapivat), an Allosteric Activator of Red Blood Cell Pyruvate Kinase

Genetic Association Studies of Red Blood Cell Transfusion Related Alloimmunization: A Systematic Review and Meta-Analysis

Complications of Extra Fluid Therapy (Hyperhydration) in Sickle Cell Patients during Vaso-Occlusive Painful Crisis

Proton Pump Inhibition for Secondary Hemochromatosis in Hereditary Anemia, a Phase III Placebo Controlled Randomized Cross-over Trial in Progress

Adding Azathioprine and Hydroxyurea Preconditioning to Alemtuzumab/TBI May Improve Donor Chimerism in Matched Sibling Donor Allogeneic Stem Cell Transplantation in Adult Sickle Cell Patients

Association of Endothelial Biomarkers with Cerebral MRI Perfusion Analysis in Patients with Sickle Cell Disease

High Incidence and Recurrence Rate of Venous Thromboembolic Events in Patients with Sickle Cell Disease

Incentive Spirometry to Prevent Acute Chest Syndrome in Adults with Sickle Cell Disease

The High Output State of Sickle Cell Patients: Associations with Anemia-Related Organ Damage

Reduced Cerebral Metabolic Rate of Oxygen in Adults with Sickle Cell Disease

Reduced Cerebrovascular Reserve Capacity in Adults with Sickle Cell Disease

Predictive Value of Gradual Change in Renal Function on Vasculopathy Related Complications and Mortality in Patients with Sickle Cell Disease

Prospective Molecular MRD Detection By NGS: A Powerful Independent Predictor for Relapse and Survival in Adults with Newly Diagnosed AML

Clofarabin Added to Standard Treatment in Adult Patients with Newly Diagnosed ALL: First Results of the Randomized Phase III HOVON-100 Study

Randomized Maintenance Therapy with Azacitidine (Vidaza) in Older Patients (≥ 60 years of age) with Acute Myeloid Leukemia (AML) and Refractory Anemia with Excess of Blasts (RAEB, RAEB-t). Results of the HOVON97 Phase III Randomized Multicentre Study (EudraCT 2008-001290-15)

Effects of Oral N -Acetylcysteine on Oxidative Stress in Patients with Sickle Cell Disease

Free Iron in Sera of Patients with Sickle Cell Disease Contributes to the Release of Neutrophil Extracellular Traps

N-Acetylcysteine in Patients with Sickle Cell Disease: A Randomized Controlled Trial

Post-Remission Treatment with Allogeneic Stem Cell Transplantation Improves Outcome in Patients Aged 60 Years and Older with Acute Myeloid Leukemia in First Remission

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only